Intops Investment
VC Fund
Yeoksamdong, South Korea
Intops Investment is a financial investment company.
- Total investments:
- 74
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Intops Investment invests in
Stages Intops Investment invests in
Countries Intops Investment invests in
Round sizes
Round size
- Seed
- $1k–$4M
- Series A
- $1.6M–$8.2M
Investment Focus
Industry
- Manufacturing 16 (22%)
- Software 12 (16%)
- Information Technology 12 (16%)
- Health Care 10 (14%)
- Biotechnology 8 (11%)
Stage
- Series A 20 (27%)
- Funding Round 17 (23%)
- Seed 14 (19%)
- Series B 7 (9%)
- Series C 6 (8%)
Country
- South Korea 62 (84%)
- China 2 (3%)
- Indonesia 1 (1%)
- United States 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Peanut AI
|
Peanut AI is a cybersecurity company that specializes in embedded protection for industrial OT and IoT systems. The company help manufacturers secure their factory equipment, PLCs, sensors, and industrial networks with lightweight and real-time defense solutions designed for global compliance. | $1.6M / Series A / Oct 16, 2025 | |
Glovv
|
Glovv is a short-form beauty content development platform. | $2.2M / Series A / Aug 19, 2025 | |
Maihub
|
Maihub develops AI-powered medical solutions designed to support healthcare providers, hospitals, and medical organizations. The company offers platforms that automate healthcare workflows, manage clinical and operational data, and assist with patient care processes. Its technology integrates artificial intelligence tools to help streamline medicalservices, improve data accessibility, and support digital healthcare operations. The company offers a wide range of AI solutions for radiology, cardiology, ophthalmology, and disease risk prediction, helping clinicians improve diagnostic accuracy and operational efficiency. maihub’s platform is currently used by more than 1,500 hospitals and clinics worldwide. | $3.2M / Series A / Jun 16, 2025 | |
Fanding
|
Fanding is a fan membership platform for content creators. | $3.4M / Series A / Apr 04, 2025 | |
Studio Galilei
|
Studio Galilei is an SFO platform company that operates and manages mobility services. | $1M / Seed / Jan 20, 2025 | |
VDream
|
VDream is a company that supports disabled people's social participation.VDream is the developer of a one-stop platform designed to offer recruitment opportunities to disabled people. | $1.1M / Series C / Dec 09, 2024 | |
CUBIG
|
CUBIG protects personal data from hyper-scale AI via privacy-preserving synthetic data by enabling data owners' pseudonymization and data de-identification data may be kept and shared safely. | Aug 19, 2024 | |
|
CUBIG
|
CUBIG protects personal data from hyper-scale AI via privacy-preserving synthetic data by enabling data owners' pseudonymization and data de-identification data may be kept and shared safely. | Seed / Aug 19, 2024 | |
AIVIS
|
AIVIS is a specialized computational pathology company that provides AI-driven solutions for the quantification of IHC biomarkers, directly addressing the "Precision Gap" in oncology and drug development. As a clinical-stage AI company, AIVIS transforms subjective slide interpretation into objective, traceable data to support bothclinical decision-making and pharmaceutical R&D. [Clinical Leadership & Market Presence] Originally established as the first official spin-off from Samsung Medical Center (SMC), AIVIS has rapidly transitioned from research to routine clinical practice. -Market Adoption: Within one year of regulatory approval, AIVIS's solutions have been deployed in over 20 leading hospitals in South Korea, capturing approximately 25% of the domestic market. -Proven Utility: In large-scale clinical studies involving 38 pathologists across 20 institutions, AIVIS demonstrated a significant reduction in inter-observer variability, drastically improving diagnostic consistency in complex cases. [Strategic Partnerships with Global Leaders] AIVIS is at the forefront of building a global digital pathology ecosystem through high-level strategic collaborations: -AstraZeneca: Signed an MOU to develop an AI-powered HER2 diagnostic ecosystem, optimizing patient screening for next-generation therapies like Antibody-Drug Conjugates (ADCs). -Philips Korea: Secured a License Agreement to integrate AIVIS’s quantification engines (Qanti® IHC) into Philips’ global pathology solutions, enhancing diagnostic workflows for various cancer biomarkers. [Comprehensive Product Portfolio] -Qanti® IHC: An MFDS-approved clinical decision support software designed for high-accuracy patient screening in routine clinical environments. It ensures auditable and regulatory-compliant data for formal diagnosis. -Qanti® Discovery: A translational research tool that automates cell quantification for drug development. It streamlines reporting for regulatory submissions and accelerates decision-making in clinical trials by providing standardized scoring. [Vision for Precision Medicine] AIVIS is continuously expanding its capabilities beyond breast and gastric cancers to include lung, prostate, and colon cancers. By co-developing specialized tools with global pharmaceutical partners, AIVIS is bridging the gap between early-stage biomarker discovery and scalable, worldwide clinical application, ensuring that every patient receives the most accurate diagnosis for personalized treatment. | $4M / Seed / Sep 16, 2023 | |
Bloomsbury Lab
|
Bloomsbury Lab specializes in manufacturing advanced projection display solutions. The company has produced screens domestically for cinema halls. The company offers cutting-edge projection solutions for various applications and environments. | $1.9M / Series A / Sep 15, 2023 | |
| See all 74 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Intops Investment invest in?
Intops Investment invests primarily in Manufacturing, Software and Information Technology startups, most often at Series A and Funding Round stage. Most of the 74 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Intops Investment's check size?
Intops Investment typically joins rounds of $1k–$4M at Seed and $1.6M–$8.2M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Intops Investment participates in.
When did Intops Investment last invest?
The most recent investment recorded for Intops Investment closed in Oct 2025. Shizune tracks 74 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
